UY38215A - METHODS AND COMPOSITIONS TO KILL A BACTERIA OF INTEREST - Google Patents
METHODS AND COMPOSITIONS TO KILL A BACTERIA OF INTERESTInfo
- Publication number
- UY38215A UY38215A UY0001038215A UY38215A UY38215A UY 38215 A UY38215 A UY 38215A UY 0001038215 A UY0001038215 A UY 0001038215A UY 38215 A UY38215 A UY 38215A UY 38215 A UY38215 A UY 38215A
- Authority
- UY
- Uruguay
- Prior art keywords
- interest
- compositions
- methods
- kill
- bacteria
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241001515965 unidentified phage Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/00041—Use of virus, viral particle or viral elements as a vector
- C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10041—Use of virus, viral particle or viral elements as a vector
- C12N2795/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10111—Myoviridae
- C12N2795/10141—Use of virus, viral particle or viral elements as a vector
- C12N2795/10143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Métodos y composiciones para matar una bacteria de interés. También se divulgan bacteriófagos modificados genéticamente.Methods and compositions for killing a bacterium of interest. Genetically modified bacteriophages are also disclosed.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862667400P | 2018-05-04 | 2018-05-04 | |
US201862743740P | 2018-10-10 | 2018-10-10 | |
US201962818066P | 2019-03-13 | 2019-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38215A true UY38215A (en) | 2019-11-29 |
Family
ID=68386731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038215A UY38215A (en) | 2018-05-04 | 2019-05-06 | METHODS AND COMPOSITIONS TO KILL A BACTERIA OF INTEREST |
Country Status (10)
Country | Link |
---|---|
US (5) | US20200354690A1 (en) |
EP (1) | EP3788152A4 (en) |
JP (1) | JP2021522857A (en) |
KR (1) | KR20210018273A (en) |
CN (1) | CN112424363A (en) |
AU (1) | AU2019262200A1 (en) |
CA (1) | CA3099316A1 (en) |
TW (1) | TW202014519A (en) |
UY (1) | UY38215A (en) |
WO (1) | WO2019213592A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102138209B1 (en) | 2015-05-06 | 2020-07-28 | 스니프르 테크놀로지스 리미티드 | Microbial population change and microbial population modification |
GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
WO2021022068A1 (en) * | 2019-07-30 | 2021-02-04 | The Regents Of The University Of California | Antimicrobial therapy through the combination of pore-forming agents and histones |
WO2021092254A1 (en) * | 2019-11-06 | 2021-05-14 | Locus Biosciences, Inc. | Phage compositions comprising crispr-cas systems and methods of use thereof |
CA3161990A1 (en) * | 2019-11-19 | 2021-05-27 | Benson Hill, Inc. | Anti-bacterial crispr compositions and methods |
WO2021195594A1 (en) * | 2020-03-26 | 2021-09-30 | San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation | Compositions and methods for treating or ameliorating infections |
WO2021231689A1 (en) * | 2020-05-14 | 2021-11-18 | Chan Zuckerberg Biohub, Inc. | Phage-mediated delivery of genes to gut microbiome |
GB202007943D0 (en) * | 2020-05-27 | 2020-07-08 | Snipr Biome Aps | Products & methods |
CA3197277A1 (en) * | 2020-11-05 | 2022-05-12 | Paul GAROFOLO | Phage compositions for escherichia comprising crispr-cas systems and methods of use thereof |
SK289101B6 (en) * | 2020-12-17 | 2023-08-09 | Ústav molekulárnej biológie Slovenskej akadémie vied, verejná výskumná inštitúcia | Antimicrobial protein, antimicrobial recombinant protein with lytic properties, expression vector, method of their preparation and use |
WO2022235816A2 (en) * | 2021-05-05 | 2022-11-10 | Locus Biosciences, Inc. | Bacteriophage comprising type i crispr-cas systems |
WO2022235799A2 (en) * | 2021-05-05 | 2022-11-10 | Locus Biosciences, Inc. | Phage compositions for staphylococcus comprising crispr-cas systems and methods of use thereof |
WO2024086532A1 (en) * | 2022-10-17 | 2024-04-25 | Locus Biosciences, Inc. | Staphylococcus phage compositions and cocktails thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2325332B1 (en) * | 2005-08-26 | 2012-10-31 | DuPont Nutrition Biosciences ApS | Use of CRISPR associated genes (CAS) |
DK2126130T3 (en) * | 2007-03-02 | 2015-06-29 | Dupont Nutrition Biosci Aps | CULTURES WITH IMPROVED phage resistance |
DK3132034T3 (en) * | 2014-04-14 | 2020-10-19 | Nemesis Bioscience Ltd | Therapeutics |
CN113215196A (en) * | 2014-06-06 | 2021-08-06 | 瑞泽恩制药公司 | Methods and compositions for modifying targeted loci |
EP3224353B9 (en) * | 2014-11-26 | 2023-08-09 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Targeted elimination of bacterial genes |
KR102138209B1 (en) * | 2015-05-06 | 2020-07-28 | 스니프르 테크놀로지스 리미티드 | Microbial population change and microbial population modification |
WO2016205276A1 (en) * | 2015-06-15 | 2016-12-22 | North Carolina State University | Methods and compositions for efficient delivery of nucleic acids and rna-based antimicrobials |
EP4089175A1 (en) * | 2015-10-13 | 2022-11-16 | Duke University | Genome engineering with type i crispr systems in eukaryotic cells |
US11311582B2 (en) * | 2015-11-19 | 2022-04-26 | Locus Biosciences, Inc. | Bacteriophage compositions and methods of use thereof |
WO2017112620A1 (en) * | 2015-12-22 | 2017-06-29 | North Carolina State University | Methods and compositions for delivery of crispr based antimicrobials |
CA3027474A1 (en) * | 2016-06-22 | 2017-12-28 | The United States Of America As Represented By The Secretary Of The Navy | Bacteriophage compositions and methods of selection of components against specific bacteria |
CA3045284A1 (en) * | 2016-12-05 | 2018-06-14 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
GB201710126D0 (en) * | 2017-06-25 | 2017-08-09 | Snipr Tech Ltd | Vectors & Methods |
DE112019001543T5 (en) | 2018-03-25 | 2020-12-17 | Snipr Biome Aps. | TREATMENT AND PREVENTION OF MICROBIAL INFECTIONS |
-
2019
- 2019-05-03 CN CN201980044965.1A patent/CN112424363A/en active Pending
- 2019-05-03 JP JP2021510294A patent/JP2021522857A/en active Pending
- 2019-05-03 TW TW108115460A patent/TW202014519A/en unknown
- 2019-05-03 KR KR1020207035088A patent/KR20210018273A/en not_active Application Discontinuation
- 2019-05-03 AU AU2019262200A patent/AU2019262200A1/en not_active Abandoned
- 2019-05-03 WO PCT/US2019/030695 patent/WO2019213592A1/en active Application Filing
- 2019-05-03 CA CA3099316A patent/CA3099316A1/en active Pending
- 2019-05-03 EP EP19796615.3A patent/EP3788152A4/en active Pending
- 2019-05-06 UY UY0001038215A patent/UY38215A/en not_active Application Discontinuation
-
2020
- 2020-06-11 US US16/899,436 patent/US20200354690A1/en not_active Abandoned
-
2021
- 2021-09-08 US US17/469,648 patent/US20220002681A1/en active Pending
-
2022
- 2022-07-06 US US17/858,899 patent/US20220387531A1/en active Pending
- 2022-07-06 US US17/858,885 patent/US20220380736A1/en active Pending
- 2022-09-16 US US17/932,812 patent/US20230038106A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019213592A1 (en) | 2019-11-07 |
AU2019262200A1 (en) | 2020-12-17 |
US20220002681A1 (en) | 2022-01-06 |
CA3099316A1 (en) | 2019-11-07 |
EP3788152A4 (en) | 2022-03-09 |
US20200354690A1 (en) | 2020-11-12 |
US20230038106A1 (en) | 2023-02-09 |
EP3788152A1 (en) | 2021-03-10 |
TW202014519A (en) | 2020-04-16 |
US20220387531A1 (en) | 2022-12-08 |
CN112424363A (en) | 2021-02-26 |
KR20210018273A (en) | 2021-02-17 |
US20220380736A1 (en) | 2022-12-01 |
JP2021522857A (en) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY38215A (en) | METHODS AND COMPOSITIONS TO KILL A BACTERIA OF INTEREST | |
EA201890817A1 (en) | CRYSTAL FORMS OF BETA-NICOTINAMIDE OF MONONUCLEOTIDE | |
EA201891201A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
BR112017024384A2 (en) | bacteria modified to reduce hyperphenylalaninemia | |
EA201890050A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
MX2017007148A (en) | Bacteria engineered to treat diseases associated with hyperammonemia. | |
EA201890047A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
EA201790294A1 (en) | FLAGELLIN BASED MEANS AND APPLICATIONS INCLUDING EFFECTIVE VACCINATION | |
ES2721001T3 (en) | Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease | |
EA201890314A3 (en) | COMPOSITIONS CONTAINING LIPOHYTOOLIGOSACCHARIDES AND MICROORGANISM TO STRENGTHEN PLANT GROWTH | |
ECSP20084373A (en) | SUBSTITUTED THIOFENCARBOXAMIDES AND ANALOGUES THEREOF | |
UY37562A (en) | BACTERIAL CEPAS, COMPOSITIONS THAT INCLUDE THEM, PLANTS AND SEEDS TREATED WITH THESE AND RELATED METHODS | |
EA201890572A1 (en) | BIOPHARMACEUTICAL COMPOSITIONS | |
MX2020006191A (en) | Therapeutic bacteriocins. | |
WO2019178487A3 (en) | Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae | |
PH12020551716A1 (en) | Anti-ror antibody constructs | |
CY1123532T1 (en) | GINGIPAIN LYSIN INHIBITORS | |
EA202190810A1 (en) | METHODS AND KITS FOR OBTAINING WHOLE BLOOD WITH INACTIVATED PATHOGEN | |
EA202091337A1 (en) | MYST FAMILY HISTONACETYLTRANSFERASE INHIBITORS | |
EA201892475A1 (en) | OXABOROLIC COMPLEX ETHERS, THEIR APPLICATION | |
CL2021002108A1 (en) | Improved endoscopic disinfectant | |
ECSP17040052A (en) | SYNERGISTIC BACTERIAL CONSORTIA TO MOBILIZE SOIL PHOSPHORUS | |
BR112022001913A2 (en) | Methods and compositions for cultivating hemoglobin-dependent bacteria | |
MX2016009094A (en) | Bioactive heme-haloperoxidase compositions and methods of their use. | |
PL409332A1 (en) | Enterococcus faecalis strains for the production of monoclonal phage preparations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20240522 |